Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells
Background: Temozolomide (TMZ), an oral alkylator of the imidazotetrazine family, is used to treat glioma. Whether this drug has any ionic effects in glioma cells remains largely unclear. Methods: With the aid of patch-clamp technology, we investigated the effects of TMZ on the ionic currents in U37...
Main Authors: | Poh-Shiow Yeh, Shyh-Jong Wu, Te-Yu Hung, Yan-Ming Huang, Chia-Wei Hsu, Chun-I Sze, Yi-Jung Hsieh, Chin-Wei Huang, Sheng-Nan Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Cell Physiol Biochem Press GmbH & Co KG
2016-05-01
|
Series: | Cellular Physiology and Biochemistry |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/443112 |
Similar Items
-
The Inhibition by Oxaliplatin, a Platinum-Based Anti-Neoplastic Agent, of the Activity of Intermediate-Conductance Ca2+-Activated K+ Channels in Human Glioma Cells
by: Mei-Han Huang, et al.
Published: (2015-10-01) -
Glycogenolysis in Acquired Glioma Resistance to Temozolomide: A Role for the [Ca2+]i-dependent Activation of Na,K-ATPase/ERK1/2 Signaling
by: Junnan Xu, et al.
Published: (2018-08-01) -
Depressive effectiveness of vigabatrin (γ-vinyl-GABA), an antiepileptic drug, in intermediate-conductance calcium-activated potassium channels in human glioma cells
by: Te-Yu Hung, et al.
Published: (2021-01-01) -
β-elemene combined with temozolomide in treatment of brain glioma
by: Xiaomin Zhang, et al.
Published: (2021-12-01) -
Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
by: Paul Daniel, et al.
Published: (2019-02-01)